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BACKGROUND: Cancer and gross-domestic-product on health expenditure (GDPHE) are critical issues for major developed countries
(MDC). Each country’s economic input, GDPHE 1980–2005 is contrasted with clinical outputs, cancer mortality rates (CMRs),
to compare their efficiency and effectiveness in reducing CMR.
METHODS: World Health Organization’s CMR data for baseline years (1979–1981) are compared with 2004–2006 by sex and age.
The w
2-tests are used to determine differences between MDC. Efficiency is analysed by calculating a ratio of average GDPHE to
reduced CMR over the period.
RESULTS: Inputs: All the countries GDPHE grew substantially. For the United Kingdom this reached 9.3%, which is below the MDC
average (10%). Outputs: CMR fell substantially (420%) in six of the ten countries. The male average (15–74 years) CMR in England
and Wales had been third highest but by 2004–2006 was sixth, a 31% reduction, which was significantly greater than seven other
countries. Initially England and Wales female average CMR was the highest of all countries and is now the second highest. There were
significantly greater reductions for the 55–64 and 65–74 years old than in seven and four countries, respectively. GDPHE reduced
CMR ratios – the average GDPHE:reduced CMR ratio of England and Wales was 1:120, greater than all MDC and double that in
four countries.
CONCLUSION: Comparing GDPHE input with CMR output showed that relatively the NHS achieved more with proportionately less
than other MDC.
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Cancer incidence in the major developed countries (MDC) has
been rising for decades (Bosetti et al, 2005; ONS, 2011) and
governments have responded by making major commitments to
reduce cancer mortality rates (CMRs) (USNCHS, 2004; D.o.H.
2006a,b) coinciding with substantial increases in gross-domestic-
product –on –health expenditure (GDPHE) (US Bureau Statistics,
2009). This raises the issue of the relative effectiveness and
efficiency of the different MDC in improving cancer outcomes. An
earlier study on survival rates that contrasted England, who had a
‘Cancer Plan’, with Wales, who did not have a plan until 3 years
later, had equivocal outcome results (Rachet et al, 2010), but the
EUROCARE cancer survival rate studies found that the United
Kingdom had done less well than many comparable affluent
countries (Berrino et al, 2007). Although it was acknowledged that
to some extent these studies were too early to examine any effect of
the new NHS investment into cancer services (Craft and Pritchard-
Jones, 2007), a more recent cancer survival study of six Western
countries again found that the United Kingdom did less well than
the other nations (Coleman et al, 2011). However there are
methodological limitations in using survival rates as a measure of
effectiveness and there is a need for caution in interpreting
country-specific survival rates (Autier and Boniol, 2011; Wegwarth
et al, 2011); though unequivocally, survival rates are improving in
most countries including the United Kingdom (Berrino et al, 2007;
Rachet et al, 2010; Coleman et al, 2011).
The current British Government’s ‘strategy for cancer’ (D.o.H.
2011) has been influenced by the United Kingdom’s relatively
poorer survival outcomes with the Department of Health high-
lighting the need to improve cancer survival rates, which in part,
has been used as justification for the proposed changes to the NHS
(Appleby, 2011). This has recently been challenged because the
Government appears to have ignored the scale and trajectory of
improvements so far attained (Pritchard and Hickish, 2008;
Appleby, 2011). The effectiveness and efficiency of health systems
is of vital importance (Buxton, 2006; Luce et al, 2006) given the
GDPHE spent by every MDC, including the proportion for cancer
services (USNCHS, 2004; D.o.H. 2006b,2011). The case for seeking
the most efficient and effective health care system is unarguably
rational (Cutler et al, 2006; Kelley, 2007) but the challenge is how
to quantify effectiveness and efficiency, based upon uniform
measures over time. Such uniform measures exists for GDPHE
Revised 1 September 2011; accepted 5 September 2011; published
online 4 October 2011
*Correspondence: Professor C Pritchard;
E-mail: cpritchard@bournemouth.ac.uk
British Journal of Cancer (2011) 105, 1788–1794
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
ybased upon US Bureau of Statistics (2010) and for CMR based
upon WHO annual mortality data (WHO, 2008).
This study addresses this challenge by examining changes in
CMR in MDC for people under 75 years of age, as reducing cancer
deaths in this age group is an objective in the British Government’s
‘strategy for cancer’ (D.o.H. 2011), within the context of a nation’s
GDPHE. Specifically, the approach used here compares economic
inputs into health, that is GDPHE, contrasted against clinical
outputs, that is reduction in CMR which serves as an indicator of
effectiveness, and derives a ratio of GDPHE against reduction in
CMR as an index of efficiency.
In taking this approach we are mindful of three significant
limitations. First, CMRs are influenced by more than just GDPHE
as the cause of, and survival from, cancer is a complex genetic–
environmental interaction, influenced by a range of socio-
economic factors, public health, and social and economic policies
(Albano et al, 2007; Sloggett et al, 2007; Rachet et al, 2009;
Lyratzopoulus et al, 2011). Second, there is a lack of uniform data
concerning the proportion of total GDPHE devoted to cancer
services. Third, CMR needs to be considered in the context of a
nation’s cancer incidence and such incidence data is itself neither
uniform nor contemporaneous with the CMR data.
There are two null hypotheses that between the end-points of
1979–1981 to 2004–2006 there will be no statistically significant
differences in the following:
(1) changes in CMR in England and Wales and the other nine
MDC by age and sex, and,
(2) in relation to GDPHE: reduced CMR ratios, the NHS in England
and Wales will not be more efficient than any other MDC.
MATERIALS AND METHODS
Eligible countries
Contrasting small with large populations can be problematic
therefore only countries with populations of more than 16 million
are reviewed and designated as ‘MDC’, which are Australia,
Canada, England and Wales, France, Germany, Italy, Japan,
Netherlands, Spain and the United States.
Economic input: (GDPHE)
The international response to dealing with health care is reflected
in national GDPHE data, which have been available from 1980
onwards (US Bureau Statistics, 2009). The percentages of GDPHE
are analysed, and an average percentage of GDPHE for the
1980–2005 period calculated and the earliest and latest current
dates will be shown.
Incidence and fiscal context of changes in CMR
Unlike GDPHE and CMR data, we could find no comparable
international uniform annual data for cancer incidence and
proportion of GDPHE specifically for cancer services in all the
countries under review for matching years but only for the six
European countries. Thus incidence and money spent on cancer
services are indicative rather than definitive but are used as a
surrogate indicator of comparable incidence of cancer and
proportional expenditure on cancers services but nothing on
Australia, Canada, Japan and the USA.
Fiscal – expenditure on cancer services In respect to the
proportion of GDPHE given to cancer services, Wilking et al
(2009) provide data as a percentage of GDPHE and direct cost per
capita based upon ‘price parity points’ (PPP), that is, cost of
comparable items in six European countries, in Euros, but for total
per capita expenditure on health presented the data in dollars.
Wilking et al (2009) provide data on sales of new cancer drugs
between 1993 and 2004, that allows us to calculate a ratio of increase
over the period and based upon general population (WHO, 2008)
we can calculate expenditure on cancer drugs per capita.
Incidence We found three authoritative sources on incidence
although they did not match temporally and their definitions of
cancer incidence varied, so comparing incidence rates between
the different sources should be considered as an estimate, but
definitive when comparing a country’s incidence within the same
data base.
(1) The OECD issued data incidence on all 10 MDC under review
but only for 2002, and for the six European countries for 2008
(OECD, 2010).
(2) Annual data are available from the Office of National Statistics
(ONS, 2011) for cases of newly registered neoplasms for
England from 1995 to 2006. However, as will be seen, when
matched with OECD data for the years 2002 and 2008, OECD is
for the whole of the United Kingdom and these rates are very
different from those reported by ONS. This may be because
of the differing definitions of cancer incidence or actual
difference in incidence. There is evidence of an association of
cancer incidence and density of population (Pritchard and
Evans, 1996) and England of course has a far higher popula-
tion density than the other home nations. However, the issue
is whether the incidence is rising as much as comparing levels
between countries. So rates are given for England (ONS, 2011)
and for the United Kingdom (OECD, 2010).
(3) Cancer incidence data were available for the USA for 1999 and
2006 (UNCHS, 2010) although these are estimates as three US
states were not included.
It is reiterated that fiscal outcomes on cancer services and
cancer incidence are an indicative context for considering uniform
and consistent data on CMR and GDPHE.
Clinical output (CMR)
Cancer mortality rates are based upon standardised WHO data (2009)
drawn from ‘all malignant neoplasm’ deaths (coded C00 – C97) in
each adult age-band for men and women separately and given in rates
per million (pm) of population. This enables comparisons to be made
between countries’ of differing size to produce a percentage or ratio
of change. The baseline years are 3-year averages for 1979–1981,
compared with the index 3-year average for 2004–2006 and
percentages of change of 0.10 (10%) have been considered as
clinically substantial (Gladen and Edfeldt, 1988).
Three age bands are compared, adults (15–74 years) based upon
the averages of all age bands and people aged 55–64 and 65–74
years for whom improved cancer services are thought most likely
to make the more significant impact (Cutler et al, 2006; Kelley,
2007) and matches the aims of successive United Kingdom
Governments (D.o.H., 2006a, 2011).
As cancer is relatively low in younger adults, the age bands
15–24 and 25–34 are combined to be the 15–34 group.
The 3-year average baseline years 1979–1981 were chosen to
match the available GDPHE data (US Bureau of Statistics, 2010),
contrasted against the latest 3-year average index years 2004–2006
(WHO, 2008), which allows for comparisons of global mortality
categories over different periods (USDHHS, 2005). The German
baseline had to be an average of 1980–1982 of the former East and
West Germany.
Some MDC latest data ended before 2006, for example,
Australia, Italy (2001–2003). To enable a direct comparison with
these countries the data for England and Wales for those years
are matched against these MDC index years. All countries used
the 10th edition of the International Classification of Disease
(WHO, 1992).
International comparison of cancer mortality rates
C Pritchard and T Hickish
1789
British Journal of Cancer (2011) 105(11), 1788–1794 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yTo provide a more clinical context, the reduction in CMR over
the period are translated into numbers of deaths if people had
continued to die at the level they did in 1979–1981, rather than the
rate found in the index years, based upon each MDC latest 15–74
year population.
Comparing England and Wales vs other MDC
The w
2-tests compare the outcomes between England and Wales
and the other MDCs for adult average (15–74) and the 55–64 and
65–74 by age bands by sex and statistical significance is at the
o0.05 probability level.
Efficiency: effectiveness ratios
To estimate a degree of efficiency between economic inputs and
reduced CMR outputs a ratio of average GDPHE to CMR
reductions over the period are calculated. As the focus is upon
the country’s efficiency the combined female and male CMR are
used in the GDPHE: CMR ratio. These ratios provide another area
of comparison for England and Wales with the other countries.
RESULTS
Economic inputs; GDPHE
Table 1 gives GDPHE for each MDC for 1980 and 2005 and an
average for the period.
Throughout the period the USA had the highest GDPHE, rising
from 9.1 to 15.3% whereas the United Kingdom went from 5.6 to
9.3%, rising from being the second lowest to sixth lowest out of the
10 countries, which equated to the second biggest increase in
GDPHE over the period only exceeded by the USA. Despite this
increase it still remained below the MDC average of 10.0% and it is
equal to the third lowest over the whole period, averaging 7.5%.
Clinical outcomes – CMR
Male CMR 1979–2006 the MDC with the current highest ‘adult’
(15–74) CMR is France at 3607 pm and Spain at 3487 pm, England
and Wales at 2869 pm were sixth highest, the lowest CMR was in
Australia 2842 pm and Japan 2863 pm.
Six countries had substantial falls (420%) over the period.
England and Wales had been the third highest at 4156 pm, falling
to 2869 pm, a 31% reduction.
Cancer mortality rates fell substantially for the 55–64 and 65–74
year olds in six and three countries, respectively, both included
England and Wales whose reductions were 35% and 28%,
respectively (Table 2).
Female CMR 1979–2006 the MDC with the highest current
‘adult’ CMR is the Netherlands at 2249 pm, followed by England
and Wales at 2202 pm, a reduction of 19% from the earlier period
when they had the highest rate. The current lowest CMR is Japan at
1404 pm and Spain 1468 pm.
It should be noted that in the three age bands, 35–44, 45–54 and
55–64, England and Wales had the biggest reduction over the period.
England and Wales and five other countries had substantial
(420%) reductions in the 45–54 age band but only the Anglo-
Welsh and Japan had substantial falls for the 55–64 age
band, whereas only Germany and Japan for the 65–74 year olds
(Table 3).
International comparisons Males: Table 4 shows that England and
Wales male average CMR fell significantly more than seven other
countries, including the USA, over the period. In regard to the 55–64
and 65–74 age bands, Anglo-Welsh male rates fell significantly more
than six countries and eight other countries, respectively.
Table 1 Total percentage of GDPHE by MDC (1980–2005) (MDC
ranked by highest average GDPHE)
Country 1980 2005
Average
1980–2005
% Change in
1980–2005
USA 9.1 15.3 12.2 68
Germany 8.7 10.7 9.7 23
France 7.1 11.1 9.1 56
Canada 7.1 9.8 8.5 38
Netherlands 7.5 9.2 8.4 23
Australia 7.0 9.5 8.3 36
Italy 7.0 8.9 8.0 27
UK 5.6 9.3 7.3 66
Japan 6.5 8.0 7.3 23
Spain 5.4 8.2 6.8 52
Total average 7.1 10.0 8.6 41
Abbreviations: GDPHE¼gross-domestic-product health expenditure; MDC¼major
developed countries.
Table 2 All malignancies (in males) (rates per million) during
1979–1981 vs 2004–2006 ranked by highest current rates
MDC, years
Average
15–74 15–34 35–44 45–54 55–64 65–74
France, 79–81 4605 112 580 2657 6034 12642
2003–2005 3607 73 389 2144 5037 10390
% change  22  35  33  19  17  18
Spain, 79–81 3317 121 480 1688 4564 9730
2003–2005 3487 70 377 1761 4696 10531
% change +5  31  21 +4 +3 +8
Italy, 79–81 4048 121 541 2282 5940 11358
2001–2003 3429 79 298 1353 4478 10939
% change  15  35  45  41  25  4
Netherlands, 79–81 4406 104 383 1702 5496 14347
2004–2006 3191 70 274 1207 3902 10531
% change  28  33  28  29  29  27
Germany, 79–81 3901 115 442 1940 4980 12027
2004–2006 3037 60 280 1338 4282 9225
% change  22  48  37  31  14  22
England and Wales,
79–81
4156 115 418 1715 5536 12998
2001–2003 3100 72 269 1201 3888 10070
% change  15  36  36  30  305  23
2002–2004 2978 74 262 1134 3750 9572
% change  30  37  37  34  32  25
2003–2005 2903 72 268 1089 3645 9443
% change  40  38  36  37  34  27
2004–2006 2869 72 261 1061 3585 9368
% change  31  38  38  38  35  28
Canada, 79–81 3542 100 390 1677 4949 10595
2002–2004 2974 59 263 1090 3731 9726
% change  16  41  33  35  25  8
USA, 79–81 3690 102 434 1891 5173 10851
2003–2005 2903 68 296 1244 3777 9128
% change  21  33  32  34  27  16
Japan, 79–81 3317 104 432 1602 4298 10150
2004–2006 2863 65 234 1152 3628 9234
% change  14  37  46  28  16  9
Australia, 79–81 3575 107 413 1620 4752 10983
2001–2003 2842 95 283 1039 3458 9333
% change  21  11  31  36  27  15
Abbreviation: MDC¼major developed countries.
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cantly more than only three other countries. In respect to the
55–64 and 65–74 age bands Anglo-Welsh female CMR declined
significantly more than six and four other countries. CMR in
Germany, Italy, Japan and Spain in the 65–74 years age band fell
significantly more than in England and Wales over the period.
Efficiency: average GDPHE:reduced CMR ratios Table 5 shows the
average GDPHE (1980–2005) against the combined gender
reduced CMR. England and Wales had the biggest overall annual
reduction of 900 pm, which divided by the 7.5% average GDPHE,
gives a ratio of 1:120. The next biggest ratios were in the
Netherlands at 1:74 and Germany 1:68.
The Anglo-Welsh GDPHE: CMR ratio was superior to all those
MDC with matched but earlier CMR and was more than double
that of Canada (1:36), Japan (1:60), Spain (1:9) and the USA (1:39).
Table 3 All malignancy deaths (in females) by age in MDC rates per
million and percentage of change during 1979 to 2006) (ranked by current
highest rate)
Country, years
Average
15–74 15–34 35–44 45–54 55–64 65–74
Netherlands, 1979–1981 2273 97 538 1579 3199 5953
2004–2006 2249 71 441 1449 3233 6031
% change  1  27  18  8+ 1+ 1
England and Wales,
1979–1981
2716 117 612 1935 4073 6844
2001–2003 2414 78 423 1374 3279 6915
% change  11  33  21  29  19 +1
2002–2004 2359 80
2 406 1344 3196 6768
% change  13  32  34  31  22  1
2003–2005 2228 75 373 1221 3019 6451
% of change  18  36  39  37  26  6
2004–2006 2202 69 374 1179 3011 6377
% of change  19  41  39  39  26  7
Canada, 1979–1981 2345 91 507 1621 3475 6031
2002–2004 2294 66 415 1286 3209 6496
% change  2  28  18  21  88
USA, 1979–1981 2328 91 494 1507 3560 5989
2003–2005 2164 65 381 1158 2903 6311
% change  7  29  23  23  18 +5
Australia, 1979–1981 2100 95 479 1447 3046 5431
2001–2003 1949 68 375 1096 2615 5593
% change  7  28  28  24  14 3
Germany (1980–1982) 2363 107 502 1470 3322 6414
2004–2006 1899 55 340 1180 2787 5131
% change  20  49  32  20  16  20
Italy, 1979–1981 2100 109 525 1373 2922 5569
2001–2003 1815 69 377 1134 2524 4973
% change  14  37  28  17  14  11
France, 1979–1981 1955 100 455 1325 2687 5208
2003–2005 1728 66 402 1221 2385 4566
% change  12  34  12  8  11  12
Spain, 1979–1981 1767 103 440 1571 2328 4391
2003–2005 1468 63 367 1015 1968 3927
% change  17  39  17  35  16  11
Japan, 1979–1981 1830 110 467 1146 2432 4996
2004–2006 1404 58 314 976 1902 3770
% change  23  48  33  15  22  25
Abbreviation: MDC¼major developed countries.
Table 4 Comparing England and Wales changed CMR (15–74 years of
age) with other MDC from 1979 to 2006 by sex
England and
Wales vs country All ages 55–64 years 65–74 years
v
2: P-value v
2: P-value v
2: P-value
Australia
Male 3.3958: n.sig 1.3445: n.sig 22.82: o0.0001
Female 1.560: n.sig 3.2761: n.sig 0.5565: n.sig
Canada
Male 21.04: o0.0001 12.4848: o0.001 128.4: o0.0001
Female 8.5524: o0.01 22.92: o0.0001 11.8958 o0.001
France
Male 12.1578: o0.001 68.83: o0.0001 42.48: o0.0001
Female 2.9207: n.sig 23.75: o0.0001 7.3656: o0.01
Germany
Male 12.3079: o0.001 90.07: o0.0001 10.3311: o0.005
Female 0.0438: n.sig 12.9373: o0.001 35.59: o0.0001
Italy
Male 14.6885: o0.001 6.0512: o0.02 133.2: o0.0001
Female 0.4325: n.sig 3.8476: o0.05 22.73: o0.0001
Japan
Male 40.29: o0.0001 1.3445: n.sig 22.827: o0.0001
Female 1.4641: n.sig 2.0929: n.sig 57.94: o0.0001
Netherlands
Male 2.0362: n.sig 9.4356: o0.01 0.9591: n.sig
Female 23.26: o0.0001 81.67: o0.0001 11.0023: o0.001
Spain
Male 142.9: o0.0001 228.6: o0.0001 418.7: o0.0001
Female 0.0778: n.sig 11.4617: o0.001 3.55239: n.sig
USA
Male 11.7845: o0.001 1.3445: n.sig 22.827: o0.0001
Female 9.1482: o0.01 7.5784: o0.01 19.8499: o0.001
Abbreviations: CMR¼cancer mortality ratio; MDC¼major developed countries;
n.sig¼not significant. Significantly better outcome values of England and Wales are
given in bold.
Table 5 Reduced male and female CMR (15–74) rates pm during 1979
to 2006) (average GDPHE to reduced deaths ratio (ranked by the biggest
ratio GDPHE:deaths))
Country, years to
2001–2006
Reduced
CMR
pm
No of deaths
saved from
1979 to 2006
Average
GDPHE
Reduced
deaths:GDPHE
ratio
England and Wales
2001–2003 679 27187 7.1 1:96
2002–2004 767 30710 7.2 1:107
2003–2005 870 34484 7.3 1:119
2004–2006 900 36032 7.5 1:120
Germany 664 54873 9.7 1:68
Netherlands 620 10135 8.4 1:74
Japan 440 42571 7.3 1:60
Italy 452 20068 8.0 1:57
France 612 37332 9.1 1:67
Australia 442 8783 8.3 1:53
USA 475 140794 12.2 1:39
Canada 310 7556 8.5 1:36
Spain 64 2154 6.8 1:9
Abbreviations: CMR¼cancer mortality ratio; GDPHE¼gross-domestic-product on
health expenditure; pm¼per million.
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that for other MDC suggests a high degree of efficiency.
CMR translated into numbers: in column three of Table 5 each
MDC reduced ‘adult’ (age 15–74) the number of deaths are shown
based upon the difference between CMR over the period. In the
USA there were annually more than 140000 fewer deaths, Germany
54000, Japan 42000 and 36000 fewer in England and Wales.
Context incidence: Table 6 provides data on incidence of
cancer for England, the United Kingdom and five other European
countries and the USA.
The incidence of new cancers in England in 2008 was 6585 per
million (pm) and it was a 2% increase over the 2002 figure,
however, based upon the OECD the latest UK rate was 2485 pm,
slightly lower than the other countries except Spain but also
showed a 2% increase over the period. OECD incidence ranges
from France at 3080pm, a 6% rise over the period down to Spain at
2485, overall averaging 2826 pm with one s.d. of 171pm, France
and Spain being more than one s.d.
The USA 2006 rate of 4806 pm was a 4% rise from their 1999 data.
Thus overall, based on all sources of data cancer incidence in
these seven countries had risen over the last 6- or 7-year period.
Expenditure on cancer services The first column in Table 7a is the
proportion of GDPHE expended on cancer services in 2007 and
shows that Germany spent proportionally most of its GDPHE on
cancer services, 7.2%, the average of the six European MDC being
6.3%, with the United Kingdom at 5.6%. However, it must be
remembered that the United Kingdom had the biggest second
increase of GDPHE over the 1980–2005 period, therefore the 5.6%
would be worth more within the context of total UK GDPHE.
The direct costs per capita for cancer reflected the above results
as column two shows that Germany spent 216 Euros compared with
the United Kingdom at 132 Euros; the average being 168 Euros.
Column three shows expenditure per capita per PPP, in dollars,
with France and Germany spending most (4$3370), with an
average for the six countries of $3020 and again the United
Kingdom being below this average at $2750.
Table 7b shows expenditure on cancer drugs in the six European
countries between 1993 and 2004 and again reflects the percentages
of GDPHE spent on cancer services. The highest was the French
expenditure per population at 21132 Euros and the United
Kingdom was lowest at 11053 Euros, with the other countries
being close to the overall average of 14997 Euros. However, apart
from Spain, the United Kingdom had the biggest proportional
increase over the period, its cancer drug bill rising by 6.81%.
Table 6 Estimates of incidences of all cancers: source is OECD, but
ONS (2011) for England and USNCHS for USA. Ranked by highest current
rates (rates per million population)
Country Total rates
England
2002 6448
2006 6092
2008 6585
% change
2002–2008 +2%
USA
1999 4611
2006 4806
% change +4%
France
2002 2895
2008 3080
% change +6%
Netherlands
2002 2830
2008 2945
% change +4%
Germany
2002 2805
OECD
2008 2885
% change +3%
Italy
2002 2765
2008 2810
% change +2%
UK
2002 2740
2008 2749
% change +2%
Spain
2002 2435
2008 2485
% change +2%
Australia
2002 3120
Canada
2002 3000
Japan
2002 2148
Abbreviations: USNCHS¼US National Center for Health Statistics; OECD¼
Organisation for Economic Co-operation and Development.
Table 7a Cancer expenditure as the percentage of GDPHE 2007 and
cost per capita patient in six countries
Country
CA costs as
percentage of
GDPHE Euro
Direct costs per
cancer per
capita Euros
Per capita total
expenditure on
health PPP, $
Germany 7.2 216 3370
France 6.6 205 3550
Italy 6.4 144 2600
Spain 6.4 141 2450
Netherlands 5.6 170 3400
UK 5.6 132 2750
Average 6.3 168 3020
Abbreviations: CA¼cancer; GDPHE=gross-domestic-product on health expendi-
ture; PPP¼price parity points. Source Wilking et al (2009).
Table 7b Sales of new cancer drugs in Europe in Euros (1000s) during
1993 to 2004 per million population (ranked by the biggest population to
cost ratio)
Country
Sales in 1993,
Euros (1000s)
Current sales,
Euros (1000s)
Ratio of
increase
Sales per
million
population
France 196020 1288844 6.61 21132
Italy 151756 904348 5.95 15698
Spain 54781 648935 11.85 14953
Germany 216841 1191208 5.49 14412
Netherlands 34854 207824 5.96 12735
UK 97710 665818 6.81 11053
Source: extrapolated from Wilking (2009).
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Limitations
One limitation of this study is the slight difference in index years
between England and Wales and Australia, Canada, France, Italy,
Spain and the USA. However, all comparative w
2-tests of reduced
CMR and the average GDPHE: reduced CMR ratios of England and
Wales were matched with the years of these countries. Moreover,
this study concerns the effectiveness and efficiency of cancer
services relative to the other MDC and not life expectancy per se,
which now finds England and Wales exceeding the USA and a
number of other MDC (US Bureau Statistics, 2009). There were
also constraints due to the unavailability of uniform estimates of
incidence of new cancers, with differing sources producing varied
rates, although irrespective of source, all the countries incidence
has increased over the last few years. There were also limits in
exploring the proportional costs of GDPHE going to cancer, to
match the consistent CMR data and GDPHE data for all 10 MDC.
Consequently the incidence and cancer-specific expenditure were
indicative contexts for changes in the CMR.
Despite these limitations this study shows the relative changes in
CMR in the context of GDPHE for the 10 MDC over the period and
the relative ‘success’ of these MDC in reducing CMR in relation to
incidence and expenditure of health.
Main findings
The hypothesis that there would be no significant differences
between England and Wales and the other nine MDC CMR can
generally be rejected. For males, the average CMR and for the
54–65 and the 65–74 age bands declined statistically significantly
more than most other MDC.
These improvements were less marked for females but there
were notable gains for the 55–64 year olds but less so for the
65–74 year olds.
The hypothesis that the NHS in England and Wales would not
be more efficient in reducing CMR in the context of its GDPHE
over the period is also rejected as the combined England and
Wales reduced CMR:GDPHE ratios were superior to all the other
countries and double the ratios found in Canada, France, Japan
and the USA, suggesting that relatively the NHS did more with
proportionally less.
However, from a practice perspective, what do these CMR
figures mean in terms of actual numbers of reduced deaths?
Transposing the Anglo-Welsh combined reductions in CMR to
number of people alive today who would not have been alive 20
years ago, there are 36000 fewer deaths annually; in Germany the
rate was equivalent to a fall of more than 54000 deaths and in the
USA a reduction of more than 140000 per year, surely an
indication of improved services.
It is noteworthy that the improvements in England and Wales
and the other countries occurred within a context of a relatively
worsening cancer incidence, but relative to other countries England
and Wales had proportionately less of general GDPHE going to
cancer services, albeit the second biggest increase of the MDC over
the last few years. Yet it would appear that it is the treatment
modalities and health care systems that has contributed most to
the better showing of the NHS as a recent study on USA expendi-
ture on adult cancer survivors have seen very substantial increases
(Short et al, 2011) but with relatively less good results. Some
American researchers (Faden et al, 2009) comparing ‘expensive
cancer drugs’ in the USA and the United Kingdom highlighted
key differences in patient’s access to such drugs concluding that
the UK system was fairer and that the ‘British system is better
structured to deal with decisions about expensive end-of-life
cancer drugs’, which reflects the findings of the use of cancer drugs
in Europe and United Kingdom by Drummond and Mason (2007).
However, there can be no grounds for complacency as, despite
public health improvements in regard to smoking, the incidence
of new cases of malignancy have increased in all countries
reviewed and depending upon baseline year, substantially so
(Pritchard and Evans, 1996; OECD, 2010; USNCHS, 2010; ONS,
2011) although these recent results suggest a possible slowing
down of the increases.
Nonetheless, with such incidence of newly diagnosed cancers
the challenge to services and resources continues in every
country.
Nevertheless, many of the people who are still alive today who
would not have been 20 or more years ago will have returned to
work and continue to contribute to the wider economy, off-setting
some of the cost of the NHS (and other health care systems), a
feature often forgotten in debates about the ‘cost’ of the NHS
(Pritchard et al, 2011).
Paradoxically, in times of economic stringency, ‘good news’
showing a reduction in mortality might be unwelcome by those
managing and running services who might fear the budget will be
cut. Rather these data show what can be achieved with increased
‘structured’ expenditure, as has occurred in England and Wales
over the past 5 years (D.o.H., 2006b). There has been controversy
concerning the merits of the NHS cancer plans in England and
Wales particularly arising from analysis of 1- and 5-year survival
data in Wales as compared with England and the timing of the
introduction of these plans (Sikora, 2009; Rachet et al, 2009;
Richards, 2009). This study with its consideration of CMR, GDPHE
and assessment of proportion of GDPHE given to cancer in the
context of cancer incidence supports these cancer plans. Indeed
given the trajectory of CMR reduction in England and the
efficiency of the system that has enabled this, any system-wide
reform in England, as planned by the British Government, should
be mindful of the elements of the system that underlie the
improvements to date.
The focus upon CMR and the substantial improvements at first
appears at odds with the findings that the cancer survival rates of
England and Wales are not as good as many other countries
(Berrino et al, 2007; Coleman et al, 2011). However, the value of
this approach in judging a nation’s cancer service – the clinical
output – is that it also examines CMR within the context of that
country’s economic input into health care and incidence of new
cancers.
We cannot explain the reasons for the discrepancy between the
survival and CMR data; this requires country-specific research.
CONCLUSIONS
In respect to England and Wales, however, our analysis adds to
other evidence indicating improvements embedded within the
health system will, if not disrupted, soon translate into improved
survival (Appleby, 2011; Pritchard and Hickish, 2011). The
planned reform of the NHS in England, which have been described
as ‘controversial and risky’ (Roland and Rosen, 2011) needs to
be considered in light of this evidence. In the assessment of
the effectiveness and efficiency of a health service, the GDPHE:
reduced CMR ratio compliments survival rate data but for England
and Wales, these results show that the NHS is comparatively
effective and efficient, delivering sustained improvement in cancer
outcomes, which rivals other MDC.
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